UPDATE 1-Merck's immunotherapy, chemo mix shows extended lung cancer gains [Reuters]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Reuters
UPDATE 1-Merck's immunotherapy, chemo mix shows extended lung cancer gains | Reuters Reuters Staff 3 Min Read * Keytruda plus chemo still shows clear benefit 18 months on * Drug combination targets large market for lung cancer * Roche, Bristol, AstraZeneca also chasing drug cocktails (Adds Merck comment) By Ben Hirschler MADRID, Sept 8 (Reuters) - Giving Merck & Co’s immunotherapy drug Keytruda in combination with chemotherapy for previously untreated advanced lung cancer appears to provide durable benefits, according to an update of a closely watched clinical trial. U.S. regulators approved the drug cocktail in May but the limited clinical trial data to date means that questions still remain as to whether it will retain its effectiveness over time. In fact, the significant improvements first reported a year ago have been maintained for more than 18 months, with the risk of disease progression or death reduced by nearly half, researchers at the European Society for Medical Oncology co
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- Life prolonging breast cancer drug recommended for PBS subsidy, but it is not time to celebratePR Web
- Global Antibiotics Market Analysis Report 2024-2030: Penicillin Drug Class Segment Led the Market in 2023, the Cephalosporin Segment is Anticipated to Register the Fastest CAGR from 2024 to 2030 [Yahoo! Finance]Yahoo! Finance
- Fusion Pharmaceuticals Mails Circular for Special Meeting of Shareholders and Announces Receipt of Interim Order [Yahoo! Finance]Yahoo! Finance
- AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain' [Yahoo! Finance]Yahoo! Finance
- AstraZeneca (AZN) Q1 Earnings & Sales Beat Estimates, Stock Up [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 4/25/24 - Form 6-K
- 4/11/24 - Form 6-K
- 4/11/24 - Form 6-K
- AZN's page on the SEC website